Showing results (11-20 of 162) with videos related to

Sort By:
Pageof 17
Gynecologic Oncology Reports|June 16, 2023
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapyBlair McNamara, Stefania Bellone, Cem Demirkiran, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|June 17, 2008
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neuAlessandro D Santin, Stefania Bellone, Juan J Roman, et al.
Gynecologic Oncology Reports|June 16, 2023
Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapyBlair McNamara, Stefania Bellone, Cem Demirkiran, et al.
Cancer Immunity|July 1, 2006
Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell cloneKevin H Kim, Ryan Dishongh, Alessandro D Santin, et al.
Current Pharmaceutical Design|October 27, 2005
Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapyAlessandro D Santin, Stefania Bellone, Juan J Roman, et al.
American Journal of Obstetrics and Gynecology|June 14, 2008
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozoleStefania Bellone, Hemendrah R Shah, Jesse K McKenney, et al.
Virology|November 8, 2011
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferationThomas G Magaldi, Laura L Almstead, Stefania Bellone, et al.
Expert Review of Anticancer Therapy|July 24, 2004
Current treatment options for endometrial cancerAlessandro D Santin, Stefania Bellone, Timothy J O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2016
Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with NivolumabAlessandro D Santin, Stefania Bellone, Natalia Buza, et al.
Gynecologic Oncology|October 8, 2003
Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapyStefania Bellone, Michela Palmieri, Murat Gokden, et al.
Pageof 17